Search for specific biomarkers of IFNβ bioactivity in patients with multiple sclerosis

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Malhotra, Sunny ^a   Bustamante, Marta F ^a   Miralles, Francisco ^a   Rio, Jordi ^a   de Villa, Mari Carmen Ruiz ^b   Vegas, Esteban ^b   Nonell, Lara ^a   Deisenhammer, Florian ^c   Fissolo, Nicolás ^a   Nurtdinov, Ramil N ^a   Montalban, Xavier ^a   Comabella, Manuel ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; GAMMA INTERFERON; MYXOVIRUS RESISTANCE PROTEIN A; NEUTRALIZING ANTIBODY; BIOLOGICAL MARKER; GUANINE NUCLEOTIDE BINDING PROTEIN; MYXOVIRUS RESISTANCE PROTEINS; PROTEINASE; USP18 PROTEIN, HUMAN;

ARTICLE; BIOLOGICAL ACTIVITY; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA MICROARRAY; DRUG SELECTIVITY; GENE; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE INDUCTION; GENETIC MARKER; HERC5 GENE; HUMAN; HUMAN CELL; IF127 GENE; IFI44L GENE; IFI6 GENE; IFIT1 GENE; IN VITRO STUDY; LY6E GENE; MULTIPLE SCLEROSIS; NEUROPATHOLOGY; PERIPHERAL BLOOD MONONUCLEAR CELL; RSAD2 GENE; SIGLEC1 GENE; TREATMENT DURATION; USP18 GENE; ADULT; CASE CONTROL STUDY; FEMALE; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; METABOLISM; TIME;

ORTHOMYXOVIRIDAE;

ADULT; ANTIBODIES, NEUTRALIZING; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; ENDOPEPTIDASES; FEMALE; GENE EXPRESSION REGULATION; GTP-BINDING PROTEINS; HUMANS; INTERFERON-BETA; MULTIPLE SCLEROSIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; TIME FACTORS;

EID: 80052008848     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0023634     Document Type: Article

References (38)

1. The Interferon β Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43: 655-661.
2. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, et al. (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann. Neurol 39: 285-294.
3. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group (1998) Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 352: 1498-1504.
4. Platanias LC, (2005) Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat. Rev. Immunol 5: 375-386.
5. Haller O, Kochs G, (2002) Interferon-induced mx proteins: dynamin-like GTPases with antiviral activity. Traffic 3: 710-717.
6. Pachner A, Narayan K, Price N, Hurd M, Dail D, (2003) MxA gene expression analysis as an interferon-beta bioactivity measurement in patients with multiple sclerosis and the identification of antibody-mediated decreased bioactivity. Mol. Diagn 7: 17-25.
7. Gilli F, Marnetto F, Caldano M, Sala A, Malucchi S, et al. (2006) Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1. Mult. Scler 12: 47-57.
8. Deisenhammer F, Reindl M, Harvey J, Gasse T, Dilitz E, et al. (1999) Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies. Neurology 52: 1239-1243.
9. Pachner AR, Bertolotto A, Deisenhammer F, (2003) Measurement of MxA mRNA or protein as a biomarker of IFNbeta bioactivity: detection of antibody-mediated decreased bioactivity (ADB). Neurology 61: S24-26.
10. Hesse D, Sellebjerg F, Sorensen PS, (2009) Absence of MxA induction by interferon beta in patients with MS reflects complete loss of bioactivity. Neurology 73: 372-377.
11. Bertolotto A, Gilli F, Sala A, Capobianco M, Malucchi S, et al. (2003) Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients. Neurology 60: 634-639.
12. Gneiss C, Tripp P, Reichartseder F, Egg R, Ehling R, et al. (2006) Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients. Mult. Scler 12: 731-737.
13. Sellebjerg F, Krakauer M, Hesse D, Ryder LP, Alsing I, et al. (2009) Identification of new sensitive biomarkers for the in vivo response to interferon-beta treatment in multiple sclerosis using DNA-array evaluation. Eur. J Neurol 16: 1291-1298.
14. Pachner AR, Warth JD, Pace A, Goelz S, INSIGHT investigators, (2009) Effect of neutralizing antibodies on biomarker responses to interferon beta: the INSIGHT study. Neurology 73: 1493-1500.
15. Malakhov MP, Malakhova OA, Kim KI, Ritchie KJ, Zhang DE, (2002) UBP43 (USP18) specifically removes ISG15 from conjugated proteins. J. Biol. Chem 277: 9976-9981.
16. Malakhov MP, Kim KI, Malakhova OA, Jacobs BS, Borden EC, et al. (2003) High-throughput immunoblotting-ubiquitinlike protein ISG15 modifies key regulators of signal transduction. J. Biol. Chem 278: 16608-16613.
17. Malakhova OA, Yan M, Malakhov MP, Yuan YZ, Ritchie KJ, et al. (2003) Protein ISGylation modulates the JAK-STAT signaling pathway. Genes Dev 17: 455-460.
18. Malakhova OA, Kim KI, Luo JK, Zou W, Kumar KG, et al. (2006) UBP43 is a novel regulator of interferon signaling independent of its ISG15 isopeptidase activity. EMBO J 25: 2358-2367.
19. Comabella M, Lünemann JD, Río J, Sánchez A, López C, et al. (2009) A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis. Brain 132: 3353-3365.
20. Van Baarsen LG, Vosslamber S, Tijssen M, Baggen JM, van der Voort LF, et al. (2008) Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients. PLoS One 3: e1927.
21. Takeuchi T, Inoue S, Yokosawa H, (2006) Identification and Herc5-mediated ISGylation of novel target proteins. Biochem. Biophys. Res. Commun 348: 473-477.
22. Van den Berg TK, Nath D, Ziltener HJ, Vestweber D, Fukuda M, et al. (2001) Cutting edge: CD43 functions as a T cell counterreceptor for the macrophage adhesion receptor sialoadhesin (Siglec-1). J Immunol 166: 3637-3640.
23. Kosugi A, Saitoh S, Noda S, Miyake K, Yamashita Y, et al. (1998) Physical and functional association between thymic shared antigen-1/stem cell antigen-2 and the T cell receptor complex. J. Biol. Chem 273: 12301-12306.
24. Pflugh DL, Maher SE, Bothwell AL, (2002) Ly-6 superfamily members Ly-6A/E, Ly-6C, and Ly-6I recognize two potential ligands expressed by B lymphocytes. J Immunol 169: 5130-5136.
25. Feng X, Wu H, Grossman JM, Hanvivadhanakul P, FitzGerald JD, et al. (2006) Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum 54: 2951-2962.
26. York MR, Nagai T, Mangini AJ, Lemaire R, van Seventer JM, et al. (2007) A macrophage marker, Siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type I interferons and toll-like receptor agonists. Arthritis Rheum 56: 1010-1020.
27. Biesen R, Demir C, Barkhudarova F, Grün JR, Steinbrich-Zöllner M, et al. (2008) Sialic acid-binding Ig-like lectin 1 expression in inflammatory and resident monocytes is a potential biomarker for monitoring disease activity and success of therapy in systemic lupus erythematosus. Arthritis Rheum 58: 1136-1145.
28. Tang J, Gu Y, Zhang M, Ye S, Chen X, et al. (2008) Increased expression of the type I interferon-inducible gene, lymphocyte antigen 6 complex locus E, in peripheral blood cells is predictive of lupus activity in a large cohort of Chinese lupus patients. Lupus 17: 805-813.
29. Serrano-Fernández P, Möller S, Goertsches R, Fiedler H, Koczan D, et al. (2010) Time course transcriptomics of IFNB1b drug therapy in multiple sclerosis. Autoimmunity 43: 172-178.
30. Tahara E Jr, Tahara H, Kanno M, Naka K, Takeda Y, et al. (2005) G1P3, an interferon inducible gene 6-16, is expressed in gastric cancers and inhibits mitochondrial-mediated apoptosis in gastric cancer cell line TMK-1 cell. Cancer Immunol. Immunother 54: 729-740.
31. Cheriyath V, Glaser KB, Waring JF, Baz R, Hussein MA, et al. (2007) G1P3, an IFN-induced survival factor, antagonizes TRAIL-induced apoptosis in human myeloma cells. J. Clin. Invest 117: 3107-3117.
32. Rosebeck S, Leaman DW, (2008) Mitochondrial localization and pro-apoptotic effects of the interferon-inducible protein ISG12a. Apoptosis 13: 562-572.
33. Wathelet MG, Clauss IM, Nols CB, Content J, Huez GA, (1987) New inducers revealed by the promoter sequence analysis of two interferon-activated human genes. Eur. J Biochem 169: 313-321.
34. Smith JB, Herschman HR, (1996) The glucocorticoid attenuated response genes GARG-16, GARG-39, and GARG-49/IRG2 encode inducible proteins containing multiple tetratricopeptide repeat domains. Arch. Biochem. Biophys 330: 290-300.
35. Li HT, Su YP, Cheng TM, Xu JM, Liao J, et al. (2010) The interaction between interferon-induced protein with tetratricopeptide repeats-1 and eukaryotic elongation factor-1A. Mol. Cell. Biochem 337: 101-110.
36. Matys V, Kel-Margoulis OV, Fricke E, Liebich I, Land S, et al. (2006) TRANSFAC and its module TRANSCompel: transcriptional gene regulation in eukaryotes. Nucleic Acids Res 34: 108-110.
37. Livak KJ, Schmittgen TD, (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
38. Satterthwaite FE, (1946) An approximate distribution of estimates of variance components. Biometrics 2: 110-114.